News

Download

Christophe Parsy, Drug Discovery Business Development Director and Mouhssin Oufir, DMPK & Bioanalytical Sciences Department Head, will be attending the Biotech Outsourcing Meeting.

We propose our Research and Development expertise in small molecules for any company to outsource new drug candidate generation by providing an Integrated Drug Discovery Service as a package or on a fee for service basis including:

• Medicinal Chemistry
• Pharmacology
• DMPK
• Safety and Toxicity 

Throughout your drug development process, we also offer you:

• Our integrated Bioanalysis Service in GPx environment for both NCE & biologics:
  • Analysis of your New Chemical and Biological Entities
  • Analysis of membrane proteins
  • Immuno-analysis
• Our DMPK expertise 
  • Early in vitro/in vivo ADME
  • Animal Pk and metabolism
  • Human Pk and metabolism

Arrange a meeting directly on the B2B plaform to meet our experts.

I fix a meeting!

Don’t miss the opportunity to listen to Dr. Christopher Housseman!

[Talk] Nanocyclix: Next Generation Kinase Therapeutics given by Dr. Christopher Housseman – Program Director – flash oral presentation about #Nanocyclix® technology: potency & selectivity to create opportunities in new therapeutic areas.
When? Wednesday, 12th June at 2:00pm!

[Poster] Nanocyclix: next generation kinase therapeutics | A chemocentric approach for the discovery of selective kinase inhibitors
And pop in to see our poster on #MedicinalChemistry & discover how #macrocyclisation is applied within Oncodesign’s projects leading to a Nanocyclix® platform.

I read the abstract!

Come and meet Dr. Fabrice Viviani, Head of the Experimentation Division and Dr. Christophe Parsy, Drug Discovery, Business Development Director, during BIO international conference networking.
Discover our unique Drug Discovery platform from patient to diagnostic and therapeutic solution.
Fix a meeting now using the BIO One-on-One Partnering platform to discuss your drug development needs!

I fix a meeting!